149 related articles for article (PubMed ID: 12188889)
21. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
22. Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxide induced oral cancer.
Srinivasan P; Suchalatha S; Babu PV; Devi RS; Narayan S; Sabitha KE; Shyamala Devi CS
Chem Biol Interact; 2008 Apr; 172(3):224-34. PubMed ID: 18336807
[TBL] [Abstract][Full Text] [Related]
23. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
24. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis.
Gonzalez FJ; Kimura S
Cancer Lett; 1999 Sep; 143(2):199-204. PubMed ID: 10503904
[TBL] [Abstract][Full Text] [Related]
25. P450 enzyme expression patterns in the NCI human tumor cell line panel.
Yu LJ; Matias J; Scudiero DA; Hite KM; Monks A; Sausville EA; Waxman DJ
Drug Metab Dispos; 2001 Mar; 29(3):304-12. PubMed ID: 11181500
[TBL] [Abstract][Full Text] [Related]
26. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.
García-Echeverría C; Fabbro D
Mini Rev Med Chem; 2004 Mar; 4(3):273-83. PubMed ID: 15032674
[TBL] [Abstract][Full Text] [Related]
27. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9.
Kent UM; Aviram M; Rosenblat M; Hollenberg PF
Drug Metab Dispos; 2002 Jun; 30(6):709-15. PubMed ID: 12019199
[TBL] [Abstract][Full Text] [Related]
28. Changes in the expression of cytochrome P450 2E1 and the activity of carcinogen-metabolizing enzymes in Schistosoma haematobium-infected human bladder tissues.
Sheweita SA; Abu El-Maati MR; El-Shahat FG; Bazeed MA
Toxicology; 2001 Apr; 162(1):43-52. PubMed ID: 11311457
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
30. Recent progress in the development of anticancer agents.
Eckhardt S
Curr Med Chem Anticancer Agents; 2002 May; 2(3):419-39. PubMed ID: 12678741
[TBL] [Abstract][Full Text] [Related]
31. Clinical strategy for the development of angiogenesis inhibitors.
Carter SK
Oncologist; 2000; 5 Suppl 1():51-4. PubMed ID: 10804092
[TBL] [Abstract][Full Text] [Related]
32. Immunochemical studies on the contribution of NADPH cytochrome P-450 reductase to the cytochrome P-450-dependent metabolism of arachidonic acid.
Schwartzman ML; Pagano PJ; McGiff JC; Abraham NG
Arch Biochem Biophys; 1987 Feb; 252(2):635-45. PubMed ID: 3101602
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
34. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenesis by chemotherapeutic agents.
Ribatti D; Vacca A; Merchionne F; Presta M
Mini Rev Med Chem; 2005 Mar; 5(3):313-7. PubMed ID: 15777265
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic strategies and agents in clinical trials.
Rosen L
Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
Yap TA; Olmos D; Brunetto AT; Tunariu N; Barriuso J; Riisnaes R; Pope L; Clark J; Futreal A; Germuska M; Collins D; deSouza NM; Leach MO; Savage RE; Waghorne C; Chai F; Garmey E; Schwartz B; Kaye SB; de Bono JS
J Clin Oncol; 2011 Apr; 29(10):1271-9. PubMed ID: 21383285
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor activity of phenoxodiol: from bench to clinic.
Alvero AB; Kelly M; Rossi P; Leiser A; Brown D; Rutherford T; Mor G
Future Oncol; 2008 Aug; 4(4):475-82. PubMed ID: 18684059
[TBL] [Abstract][Full Text] [Related]
39. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
Wong MS; Sidik SM; Mahmud R; Stanslas J
Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
